- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02565667
A Prospective Clinical Study for Transanal Double Purse-string Rectal Anastomosis Preformed With KOL Stapler
A Prospective Randomized Clinical Study for Transanal Double Purse-string Rectal Anastomosis Preformed With KOL Stapler
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
About 5-10% of patients receiving low rectal resection using traditional anastomosis occurred anastomotic leak, risk factors for which included patient related (age, gender, tumor distance from the anal verge), hypoproteinemia, diabetes mellitus, etc), procedure related (emergency) and technical related (one stapler, double stapler or handsewn).
Anastomotic leak caused prolonged hospital stay, delayed post-operative adjuvant radiochemotherapy and need of stoma in some cases. Besides, anastomotic leak was reported to be associated with increased local recurrence rate. Thus, it's of great importance to develop new surgical devices to prevent "dog ear" problem and reduce the anastomotic leak rate.
Double stapled pursestring anastomosis was the one of the most widely used methods in lower rectal resection. One major problem of this procedure was creating one or double side "dog ear" phenomenon (Dis Colon Rectum. 2000 Apr;43(4):522-5. Fig 1). This weak spot was theoretically responsible for post-operative anastomotic leak as demonstrated by animal experiments and clinical practice.
In this clinical trial, we used a transanal double purse-string rectal anastomosis preformed with KOL stapler for lower rectal resection. This procedure would resolve the dog ear problem through circular anastomosis taking care that the anastomotic site contained only gut tissues without any staples. We aim to demonstrate the safety, effectiveness of this procedure and establish a standard method for laparoscopic (ultra-)low anterior rectal resection.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Li Xin-Xiang, M.D & Ph.D.
- Phone Number: +86-18017312900
- Email: lxx1149@163.com
Study Contact Backup
- Name: Li Yi-Wei, M.D & Ph.D.
- Phone Number: +86-18121299437
- Email: liyiwei1981@gmail.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Recruiting
- Fudan University Shanghai Cancer Center
-
Sub-Investigator:
- YIWEI LI, DOCTOR
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- pathological confirmed rectal adenocarcinoma
- less than 10 cm of distal tumor margin from the anal edge
- less than 4 cm of maximum tumor diameter and less than 1/2 of circumference diameter
- tumor stage earlier than cT1-3N0M0 before surgery or that following neoadjuvant radiochemotherapy
- normal defecation function (Wexner score < 4)
- open or laparoscopic operation
Exclusion Criteria:
- recurrent cases
- emergency including obstruction, bleeding or perforation
- severe abdominal adhesions
- severe malnutrition can not be improved before surgery
- can not tolerate to surgery due to severe comorbidities of heart, lung, liver or kidney
- refractory hypoproteinemia or diabetes mellitus
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: KOL group
KOL stapler was used for rectal anastomosis
|
KOL staple was used for rectal anastomosis
|
ACTIVE_COMPARATOR: traditional stapler group
traditional stapler was used for rectal anastomosis
|
traditional staple was used for rectal anastomosis
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
anastomotic leak rate
Time Frame: 30 days since the date of surgery
|
percentage of patients occuring anastomotic leak within 30 days since surgery
|
30 days since the date of surgery
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
post-operative anal function
Time Frame: within one year since the date of surgery
|
within one year since the date of surgery
|
30-day mortality rate
Time Frame: within 30 days since the date of surgery
|
within 30 days since the date of surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Li Xin-Xiang, M.D & Ph.D., Shanghai Cancer Center, Fudan University, #270 Dong An Road, Shanghai, 200030
Publications and helpful links
General Publications
- Trencheva K, Morrissey KP, Wells M, Mancuso CA, Lee SW, Sonoda T, Michelassi F, Charlson ME, Milsom JW. Identifying important predictors for anastomotic leak after colon and rectal resection: prospective study on 616 patients. Ann Surg. 2013 Jan;257(1):108-13. doi: 10.1097/SLA.0b013e318262a6cd.
- Midura EF, Hanseman D, Davis BR, Atkinson SJ, Abbott DE, Shah SA, Paquette IM. Risk factors and consequences of anastomotic leak after colectomy: a national analysis. Dis Colon Rectum. 2015 Mar;58(3):333-8. doi: 10.1097/DCR.0000000000000249.
- Espin E, Ciga MA, Pera M, Ortiz H; Spanish Rectal Cancer Project. Oncological outcome following anastomotic leak in rectal surgery. Br J Surg. 2015 Mar;102(4):416-22. doi: 10.1002/bjs.9748. Epub 2015 Jan 26.
- Morse BC, Simpson JP, Jones YR, Johnson BL, Knott BM, Kotrady JA. Determination of independent predictive factors for anastomotic leak: analysis of 682 intestinal anastomoses. Am J Surg. 2013 Dec;206(6):950-5; discussion 955-6. doi: 10.1016/j.amjsurg.2013.07.017. Epub 2013 Sep 24.
- Mirnezami A, Mirnezami R, Chandrakumaran K, Sasapu K, Sagar P, Finan P. Increased local recurrence and reduced survival from colorectal cancer following anastomotic leak: systematic review and meta-analysis. Ann Surg. 2011 May;253(5):890-9. doi: 10.1097/SLA.0b013e3182128929.
- Roumen RM, Rahusen FT, Wijnen MH, Croiset van Uchelen FA. "Dog ear" formation after double-stapled low anterior resection as a risk factor for anastomotic disruption. Dis Colon Rectum. 2000 Apr;43(4):522-5. doi: 10.1007/BF02237198.
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FudanKOL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rectal Neoplasms
-
Ohio State University Comprehensive Cancer CenterNovartis Pharmaceuticals; National Comprehensive Cancer NetworkCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Recurrent Rectal CancerUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Rectal AdenocarcinomaUnited States
-
SafeHeal IncTerminatedSafeHeal Colovac Colorectal Anastomosis Protection Device Evaluation (SAFE-2) Pivotal Study (SAFE-2)Colorectal Cancer | Rectal Cancer | Rectal Tumor | Rectal/AnalUnited States, France, Belgium
-
National Cancer Institute (NCI)NRG OncologyCompletedRectal Adenocarcinoma | Stage III Rectal Cancer AJCC v7 | Stage II Rectal Cancer AJCC v7United States, Puerto Rico
-
National Cancer Institute (NCI)TerminatedStage III Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage II Rectal Cancer AJCC v8 | Locally Advanced Rectal CarcinomaUnited States
-
City of Hope Medical CenterWithdrawnRecurrent Rectal Cancer | Stage I Rectal Cancer | Stage II Rectal Cancer | Stage III Rectal Cancer
-
OHSU Knight Cancer InstituteOregon Health and Science University; Taiho Pharmaceutical Co., Ltd.RecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8United States
-
Peking University Third HospitalRecruitingRectal Cancer Stage II | Rectal Cancer Stage IIIChina
-
Prof. Dr. med. Claus RödelJohann Wolfgang Goethe University Hospital; Deutsche Krebshilfe e.V., Bonn...CompletedRectal Neoplasms | Rectal Cancer Stage II | Rectal Cancer Stage IIIGermany
-
GlaxoSmithKlineRecruitingNeoplasms, RectalUnited States, France, Italy, Japan, Spain, United Kingdom, Germany, Korea, Republic of, Canada, Netherlands